| Literature DB >> 29451535 |
Daniël A Korevaar1, Jérémie F Cohen1,2, Johannes B Reitsma3, David E Bruns4, Constantine A Gatsonis5, Paul P Glasziou6, Les Irwig7, David Moher8,9, Henrica C W de Vet10, Douglas G Altman11, Lotty Hooft12, Patrick M M Bossuyt1.
Abstract
BACKGROUND: Although the number of reporting guidelines has grown rapidly, few have gone through an updating process. The STARD statement (Standards for Reporting Diagnostic Accuracy), published in 2003 to help improve the transparency and completeness of reporting of diagnostic accuracy studies, was recently updated in a systematic way. Here, we describe the steps taken and a justification for the changes made.Entities:
Keywords: CONSORT; Diagnostic accuracy; EQUATOR; Reporting quality; Research waste; STARD; Sensitivity and specificity
Year: 2016 PMID: 29451535 PMCID: PMC5803584 DOI: 10.1186/s41073-016-0014-7
Source DB: PubMed Journal: Res Integr Peer Rev ISSN: 2058-8615
Fig. 1Milestones in the development of STARD 2015
The STARD 2015 list
| Section and topic | No. | Item |
|---|---|---|
| Title or abstract | ||
| 1 | Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC) | |
| Abstract | ||
| 2 | Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts) | |
| Introduction | ||
| 3 | Scientific and clinical background, including the intended use and clinical role of the index test | |
| 4 | Study objectives and hypotheses | |
| Methods | ||
| Study design | 5 | Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study) |
| Participants | 6 | Eligibility criteria |
| 7 | On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry) | |
| 8 | Where and when potentially eligible participants were identified (setting, location, and dates) | |
| 9 | Whether participants formed a consecutive, random, or convenience series | |
| Test methods | 10a | Index test, in sufficient detail to allow replication |
| 10b | Reference standard, in sufficient detail to allow replication | |
| 11 | Rationale for choosing the reference standard (if alternatives exist) | |
| 12a | Definition of and rationale for test positivity cutoffs or result categories of the index test, distinguishing pre-specified from exploratory | |
| 12b | Definition of and rationale for test positivity cutoffs or result categories of the reference standard, distinguishing pre-specified from exploratory | |
| 13a | Whether clinical information and reference standard results were available to the performers or readers of the index test | |
| 13b | Whether clinical information and index test results were available to the assessors of the reference standard | |
| Analysis | 14 | Methods for estimating or comparing measures of diagnostic accuracy |
| 15 | How indeterminate index test or reference standard results were handled | |
| 16 | How missing data on the index test and reference standard were handled | |
| 17 | Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory | |
| 18 | Intended sample size and how it was determined | |
| Results | ||
| Participants | 19 | Flow of participants, using a diagram |
| 20 | Baseline demographic and clinical characteristics of participants | |
| 21a | Distribution of severity of disease in those with the target condition | |
| 21b | Distribution of alternative diagnoses in those without the target condition | |
| 22 | Time interval and any clinical interventions between index test and reference standard | |
| Test results | 23 | Cross tabulation of the index test results (or their distribution) by the results of the reference standard |
| 24 | Estimates of diagnostic accuracy and their precision (such as 95 % confidence intervals) | |
| 25 | Any adverse events from performing the index test or the reference standard | |
| Discussion | ||
| 26 | Study limitations, including sources of potential bias, statistical uncertainty, and generalizability | |
| 27 | Implications for practice, including the intended use and clinical role of the index test | |
| Other information | ||
| 28 | Registration number and name of registry | |
| 29 | Where the full study protocol can be accessed | |
| 30 | Sources of funding and other support; role of funders | |
Summary of main changes in STARD 2015
| Section | Authors are invited to.. |
|---|---|
| Title/abstract | report a structured abstract, according to STARD for Abstracts (item 2). |
| Introduction | report the intended use and clinical role of the index test under investigations (item 3), along with specific study hypotheses (item 4). |
| Methods | report whether test positivity cutoffs or result categories were pre-specified or exploratory (item 12), whether analyses of variability in diagnostic accuracy were pre-specified or exploratory (item 17), and how they determined the intended sample size (item 18). |
| Results | always provide a diagram, illustrating the flow of participants through the study (item 19). |
| Discussion | discuss potential study limitations (item 26) and the implications for practice of the study findings (item 27). |
| Other information | report the registration number (item 28), where the full study protocol can be accessed (item 29), and sources of funding (item 30). |
A detailed overview of the changes made in STARD 2015, and the rationale for these changes, is provided in Additional file 9
Fig. 2Prototypical STARD diagram to report flow of participants through the study